MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End-use, By Workflow, By Region & Competition, 2021-2031F

Description

The Global MiRNA Sequencing and Assay Market is projected to expand from USD 24.26 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 6.58%. These genomic technologies encompass methods designed to detect and quantify small non-coding RNA molecules that play a crucial role in regulating gene expression. This market trajectory is primarily driven by the increasing prevalence of chronic conditions, particularly cancer, which creates a strong demand for advanced biomarker discovery tools essential for early diagnosis and patient stratification. Additionally, the broader implementation of precision medicine initiatives and increased funding for genomic research provide substantial momentum for the sector's growth.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 24.26 Billion
Market Size 2031	USD 35.56 Billion
CAGR 2026-2031	6.58%
Fastest Growing Segment	Sequencing By Synthesis
Largest Market	North America

Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.

Market Driver

The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.

Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.

Market Challenge

A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.

This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.

Market Trends

The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels. This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.

Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies. Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.

Key Market Players

Thermo Fisher Scientific, Inc.
Illumina, Inc.
QIAGEN N.V.
PerkinElmer, Inc.
Abcam plc
New England Biolabs, Inc.
Takara Bio USA Inc.
Lexogen GmbH
Norgen Biotek Corp.
Maravai LifeSciences Holdings, Inc

Report Scope

In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

MiRNA Sequencing and Assay Market, By Technology

Sequencing by Synthesis
Sequencing by Oligonucleotide Ligation and Detection (SOLiD)
Nanopore Sequencing
Sanger Sequencing
Single Molecule Real-time (SMRT) Sequencing

MiRNA Sequencing and Assay Market, By Application

Cancer
Polyglutamine Diseases
Autoimmune Disease
Schizophrenia
Others

MiRNA Sequencing and Assay Market, By End-use

Pharmaceutical & Biotechnology Industry
Research and Academic Institutes
Others

MiRNA Sequencing and Assay Market, By Workflow

Library Preparation
Sequencing
Data Analysis & Storage

MiRNA Sequencing and Assay Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.

Available Customizations:

Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global MiRNA Sequencing and Assay Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing)
- 5.2.2. By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others)
- 5.2.3. By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others)
- 5.2.4. By Workflow (Library Preparation, Sequencing, Data Analysis & Storage)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America MiRNA Sequencing and Assay Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Application
- 6.2.3. By End-use
- 6.2.4. By Workflow
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States MiRNA Sequencing and Assay Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By End-use
    - 6.3.1.2.4. By Workflow
- 6.3.2. Canada MiRNA Sequencing and Assay Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By End-use
    - 6.3.2.2.4. By Workflow
- 6.3.3. Mexico MiRNA Sequencing and Assay Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By End-use
    - 6.3.3.2.4. By Workflow

7. Europe MiRNA Sequencing and Assay Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Application
- 7.2.3. By End-use
- 7.2.4. By Workflow
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany MiRNA Sequencing and Assay Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By End-use
    - 7.3.1.2.4. By Workflow
- 7.3.2. France MiRNA Sequencing and Assay Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By End-use
    - 7.3.2.2.4. By Workflow
- 7.3.3. United Kingdom MiRNA Sequencing and Assay Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By End-use
    - 7.3.3.2.4. By Workflow
- 7.3.4. Italy MiRNA Sequencing and Assay Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By End-use
    - 7.3.4.2.4. By Workflow
- 7.3.5. Spain MiRNA Sequencing and Assay Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By End-use
    - 7.3.5.2.4. By Workflow

8. Asia Pacific MiRNA Sequencing and Assay Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Application
- 8.2.3. By End-use
- 8.2.4. By Workflow
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China MiRNA Sequencing and Assay Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By End-use
    - 8.3.1.2.4. By Workflow
- 8.3.2. India MiRNA Sequencing and Assay Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By End-use
    - 8.3.2.2.4. By Workflow
- 8.3.3. Japan MiRNA Sequencing and Assay Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By End-use
    - 8.3.3.2.4. By Workflow
- 8.3.4. South Korea MiRNA Sequencing and Assay Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Technology
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By End-use
    - 8.3.4.2.4. By Workflow
- 8.3.5. Australia MiRNA Sequencing and Assay Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Technology
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By End-use
    - 8.3.5.2.4. By Workflow

9. Middle East & Africa MiRNA Sequencing and Assay Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Application
- 9.2.3. By End-use
- 9.2.4. By Workflow
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia MiRNA Sequencing and Assay Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By End-use
    - 9.3.1.2.4. By Workflow
- 9.3.2. UAE MiRNA Sequencing and Assay Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By End-use
    - 9.3.2.2.4. By Workflow
- 9.3.3. South Africa MiRNA Sequencing and Assay Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By End-use
    - 9.3.3.2.4. By Workflow

10. South America MiRNA Sequencing and Assay Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Application
- 10.2.3. By End-use
- 10.2.4. By Workflow
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil MiRNA Sequencing and Assay Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By End-use
    - 10.3.1.2.4. By Workflow
- 10.3.2. Colombia MiRNA Sequencing and Assay Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By End-use
    - 10.3.2.2.4. By Workflow
- 10.3.3. Argentina MiRNA Sequencing and Assay Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By End-use
    - 10.3.3.2.4. By Workflow

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global MiRNA Sequencing and Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Thermo Fisher Scientific, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Illumina, Inc.
15.3. QIAGEN N.V.
15.4. PerkinElmer, Inc.
15.5. Abcam plc
15.6. New England Biolabs, Inc.
15.7. Takara Bio USA Inc.
15.8. Lexogen GmbH
15.9. Norgen Biotek Corp.
15.10. Maravai LifeSciences Holdings, Inc